Teva's MS drug Copaxone has strong second-quarter sales

JERUSALEM, July 30 (Reuters) - Teva Pharmaceutical Industries, which this week revealed plans to buy Allergan's generics drugs business in a $40.5 billion deal, said on Thursday sales of its branded multiple sclerosis drug Copaxone rose 12 percent in the second quarter even though it faces new competition.